摘要
目的 观察多西他赛（docetaxel）联用卡铂（carboplatin）对晚期非小细胞肺癌一线治疗的疗效和毒性反应.方法 晚期非小细胞肺癌患者共31例,多西他赛用量75 mg/m^2,第1天静脉滴注,卡铂AUC=5 mg·mL^-1·min^-1,第1天静脉滴注.21～28 d为1个疗程,每例患者至少接受2个疗程治疗.结果 31例患者均可评价疗效,无完全缓解病例（CR）,11例获部分缓解（PR）,16例稳定（SD）,4例疾病进展（PD）,总有效率为35.5%（11/31）,其中位疾病进展时间为4.5个月,中位生存时间10.2个月（3～20个月）,1年生存率为45.1%,毒性反应主要有骨髓抑制、恶心、呕吐和腹泻以及白细胞下降导致的发热等.大部分患者为Ⅰ、Ⅱ度反应,患者耐受良好.结论 多西他赛联合卡铂是一种对晚期非小细胞肺癌有效的治疗方法,毒性反应轻,临床使用安全.
Objective To evaluate the clinical response rate and toxic reaction of docetaxel combination with carboplatin as front-line therapy in advanced non-small cell lung cancer （NSCLC）. Methods A total of 31 chemotherapynaive patients with stage ⅢB or Ⅳ NSCLC were enrolled in this study, Docetaxel was given at a dose of 75 mg/m^2 over an 1 hour iv. infusion on day 1. Carboplatin dosed to an area under the time-concentration curve （AUC） of 5 mg·mL^-1·min^-1 was administered iv. on day 1. The chemotherapy was repeated every 21-28 days. Each patient was given at least 2 cycles. Results The response rate of all the patients were evaluated. There were 11 PR, 16 SD and 4 PD in the group. The overall response rate was 35.5% （11/31）. Median time to progression （TTP） was 4.5 months. Median survival duration was 10.2 months（3-20 months）, one year survival rate was 45.1%. The major toxicity included neutropenia, vomiting and diarrhea, impaired liver function, febrile neutropenia. The severity of these side was grade Ⅰ-Ⅱ and well tolerated. Conclusion Docetaxel combination with carboplatin is effective in the treatment of advanced non-small cell lung cancer, with mild to moderate side effect and safety in clinical practice.
出处
《山西医药杂志》
CAS
2007年第5期397-399,共3页
Shanxi Medical Journal
关键词
癌
非小细胞肺
药物疗法
多西他赛
卡铂
Carcinoma,non-small-cell lung
Drug therapy
Docetaxel
Carboplatin
